| pubmed-article:10661767 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10661767 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:10661767 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:10661767 | lifeskim:mentions | umls-concept:C0596290 | lld:lifeskim |
| pubmed-article:10661767 | lifeskim:mentions | umls-concept:C0006233 | lld:lifeskim |
| pubmed-article:10661767 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:10661767 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10661767 | pubmed:dateCreated | 2000-2-29 | lld:pubmed |
| pubmed-article:10661767 | pubmed:abstractText | In oncology, a number of new potential therapeutic modalities, including gene targeting, are currently under investigation. To evaluate their response at a preclinical level, a non-invasive method providing information about cell proliferation would be highly valuable. The growth fraction can be assessed by the incorporation of thymidine into the DNA of S-phase cells. We report the use of the thymidine analogue bromodeoxyuridine (BrUdR) labelled with bromide-76 (76Br) in positron emission tomography (PET). PET scans using [76Br]BrUdR were performed in seven patients with metastatic melanoma. The in vitro cell proliferation in these metastases (n = 7) was compared with immunohistochemically evaluated cell proliferation using anti-bromo-deoxyuridine and MIB-1 antibodies after excision. Blood samples were taken to analyse the kinetics of the radiopharmaceutical. The accumulation of [76Br]BrUdR in PET correlated significantly with the immunohistochemically assessment of S-phase and cycling cells. In one patient a clinically unexpected metastases was found on [76Br]BrUdR-PET which became evident 4 weeks later. Analysis of blood samples showed a fast disappearance of [76Br]BrUdR; 30 min after injection free bromide was the main form of radioactivity, resulting in a high background activity. Assessment of cell proliferation using [76Br]BrUdR is hampered because of fast debromation and high background activity. The results are thus rather the effect of the increased circulation in more rapidly proliferating metastases than Incorporation of [76Br]BrUdR into proliferating cells. | lld:pubmed |
| pubmed-article:10661767 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10661767 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10661767 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10661767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10661767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10661767 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10661767 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:10661767 | pubmed:issn | 0960-8931 | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:SchubigerP... | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:BläuensteinPP | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:DummerRR | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:BöniRR | lld:pubmed |
| pubmed-article:10661767 | pubmed:author | pubmed-author:SteinertH CHC | lld:pubmed |
| pubmed-article:10661767 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10661767 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:10661767 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10661767 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10661767 | pubmed:pagination | 569-73 | lld:pubmed |
| pubmed-article:10661767 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:meshHeading | pubmed-meshheading:10661767... | lld:pubmed |
| pubmed-article:10661767 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10661767 | pubmed:articleTitle | Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine. | lld:pubmed |
| pubmed-article:10661767 | pubmed:affiliation | Department of Dermatology, University Hospital, Zürich, Switzerland. | lld:pubmed |
| pubmed-article:10661767 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10661767 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
